Malignant Digestive System Neoplasm

Phase 2 trial of adult hepatocellular patients treated with sunitinib analyzed how baseline concentration of different soluble VEGF proteins predict overall survival (OS) and time to progression (TTP)… (full text at CIViC)

PMID 21787417 · Harmon et al., 2011 · Open in CIViC

Gene symbol publication providing minimal information. A VHL gene mutation at codon 111, AGC-ATC, Ser-Ile is associated to pancreatic cancer. It is unclear if this variant is somatic or germline. It i… (full text at CIViC)

PMID 10942118 · Bradley et al., 2000 · Open in CIViC

In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC)

PMID 29802158 · Heining et al., 2018 · Open in CIViC

In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC)

PMID 29802158 · Heining et al., 2018 · Open in CIViC

A patient with pancreatic cancer harboring NTRK fusion was treated with larotrectinib. The best overall response was PR at 2 months but the tumor progressed after 6 months.

PMID 31605106 · O'Reilly et al., 2019 · Open in CIViC

In a Phase I/II study of Larotrectinib, highly selective TRK inhibitor, one patient with pancreatic cancer with NTRK fusion showed PR.

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

In a Phase I/II study of Larotrectinib, highly selective TRK inhibitor, two patient with cholangiocarcinoma with NTRK fusion was enrolled. One of the two patient showed PR.

The authors describe the creation of a data portal containing over 20,000 gene fusions identified in 9,966 cancer samples and 648 normal samples from The Cancer Genome Atlas. The VPS18-NTRK3 e4::e18 f… (full text at CIViC)

PMID 29099951 · Hu et al., 2018 · Open in CIViC

A tissue microarray of 268 patients with histologically confirmed colorectal adenocarcinoma was performed to search for ROS1 gene fusion events to guide potential targeted therapy in future cases. Bre… (full text at CIViC)

PMID 24296758 · Aisner et al., 2014 · Open in CIViC

Within a preclinical study the inhibitory effects of AZD1775 in esophageal squamous cell carcinoma (ESCC) was demonstrated in both in vitro and in-vivo samples that predominantly displayed high expres… (full text at CIViC)

PMID 31427973 · Bi et al., 2019 · Open in CIViC

Expression of secreted factor Wnt-11 is increased in several types of cancer, including colorectal cancer, where it promotes cancer cell migration and invasion. Analysis of colorectal cancer gene expr… (full text at CIViC)

PMID 31261741 · Gorroño-Etxebarria et al., 2019 · Open in CIViC

In the AOM–DSS mouse colon tumor model (n = 8/group), aspirin (28 mg/kg/day) reduced tumor number and decreased epithelial proliferation (Ki67 and BrdU staining) and lowered circulating pro-inflammato… (full text at CIViC)

PMID 34033814 · Feng et al., 2021 · Open in CIViC

YAP1 up-regulation of EGFR plays an important role in conferring therapy resistance to 5-FU or docetaxel in esophageal cancer (EC) cells. Inhibitor of YAP1, Verteporfin, can overcome the acquired chem… (full text at CIViC)

PMID 25739674 · Song et al., 2015 · Open in CIViC

YAP1 up-regulation of EGFR plays an important role in conferring therapy resistance to 5-FU or docetaxel in esophageal cancer (EC) cells. Inhibitor of YAP1, Verteporfin, can overcome the acquired chem… (full text at CIViC)

PMID 25739674 · Song et al., 2015 · Open in CIViC

The oxaliplatin resistant HCT116/OXA cell line shows increased EMT phenotype, as well as cell invasion and migration ability compared to parental HCT116 cells. The EMT-associated transcription factor … (full text at CIViC)

PMID 29151941 · Guo et al., 2017 · Open in CIViC

In a cohort of 118 CC patients, ZEB1 had high expression in 66.9% and low expression in 33.1% of patients by IHC. Median OS was longer in the ZEB1 low expression group (14.0 months, 95% CI 11.63-14.97… (full text at CIViC)

PMID 29151941 · Guo et al., 2017 · Open in CIViC